Year: 2025

Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flows Continued expansion of commercial partnerships for pipeline assets Alvotech listed on Nasdaq Stockholm Market Conference call and live webcast on Thursday August 14, 2025, 8:00 am ET (12:00pm GMT)REYKJAVIK, Iceland, August 13, 2025 – Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live webcast on August 14, 2025, at 8:00 am ET (12:00 pm GMT). “The strong results from the first...

Strong performance driven by over 200% growth in product revenues year-on-yearBest quarter in Alvotech’s history in terms of operating cash flowsContinued expansion of commercial partnerships for pipeline assetsAlvotech listed on Nasdaq Stockholm MarketConference call and live webcast on Thursday August 14, 2025, 8:00 am ET (12:00pm GMT)REYKJAVIK, Iceland, Aug. 13, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live webcast on August 14, 2025, at 8:00 am ET (12:00 pm GMT). “The strong...

A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model $1.97 million cash on hand, runway through March 31, 2026WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today its financial results for the second quarter of 2025, ended June 30, 2025. While net product revenues declined compared to Q2 2024 due to a now resolved supply chain disruption, the Company reported an increase in profitability, largely attributed to cash-pay patients using KODATEF® (tafenoquine) 16-count boxes which were imported with U.S. Food and Drug Administration (FDA) consent to help mitigate a temporary...

MINNETONKA, Minn., Aug. 13, 2025 (GLOBE NEWSWIRE) — Table Trac, Inc. (OTCQX: TBTC), a developer and provider of casino information and management systems that automate and monitor the operations of casinos, announced financial results for the three and six months ending June 30, 2025. The 10-Q can be found @ http://www.sec.gov Second Quarter 2025 HighlightsThe Company installed one system at a new customer location. The Company had two customers with system contracts in backlog as of June 30, 2025. The company anticipates that these contracts will be installed during the third quarter of 2025. As of the filing date of this report, the Company signed one new contract.Second Quarter 2025 Financial ResultsMaintenance revenues increased 19.4% from $1.32M in 2024 to $1.58M in 2025.The following table provides a reconciliation...

CHICO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — Lulu’s Fashion Lounge Holdings, Inc. (“Lulus” or the “Company”) (Nasdaq: LVLU) today reported financial results for the second quarter ended June 29, 2025 and updated its Adjusted EBITDA financial outlook for the third quarter ending September 28, 2025 and its capital expenditure outlook for the year ending December 28, 2025. Crystal Landsem, CEO and Interim CFO of Lulus, said: “In the second quarter, we saw meaningful sequential improvement in our quarterly year-over-year net revenue comparison, and we continued to see positive sales momentum in occasion dresses, led by our bridesmaid category. This performance was offset by continued softness in casual wear and footwear, which we are actively repositioning to better align with our strengths in event attire. We remain encouraged...

Tariff Mitigation Strategies, Cost Optimization Plan, New Product Introductions, and Sales Channel Expansion Position the Company for Improved Performance SUMMIT, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) — Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”), a consumer products company, today announced financial results for the second quarter ended June 30, 2025 (“Q2 2025”) and provided net revenue and Adjusted EBITDA guidance for the six months ending December 31, 2025. “The second quarter tested our resilience against significant tariff volatility, and our team responded with swift, decisive actions to put the business back on a path towards stabilization. We believe the most disruptive impacts are now behind us,” said Arturo Rodriguez, Chief Executive Officer. “By focusing on those areas that we can control, we met our...

Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing GLP-1RA therapy, while Phase 2 STRENGTH trial to focus on durable weight loss as a monotherapy and in combination with GLP-1RA. Anticipated expansion of Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS) to include pediatric population younger than 13 years of age. $141.8 million in cash, cash equivalents, and short-term investments supports projected operations into 2027.SAN DIEGO, Aug. 13, 2025 (GLOBE NEWSWIRE) — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

MSGM Resports Q2 2025 Financial ResultsMotorsport Games Inc is reporting on its Q2 2025 Financial ResultsMIAMI, Aug. 13, 2025 (GLOBE NEWSWIRE) — Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games” or “the Company”) today reported financial results for its second quarter ended June 30, 2025. The Company has also posted the second quarter 2025 earnings slides highlighting key milestones that occurred during and subsequent to the period, which are accessible on the Company’s investor relations website. “Q2 2025 has been an incredible period of growth for our Company,” commented Stephen Hood, President and Chief Executive Officer of Motorsport Games. “The Le Mans Ultimate team at Studio 397 utilized greatly the attention that the ‘real-world’ 24 hours of Le Mans attracts and delivered key features alongside strong marketing...

Delivers positive operating income Second quarter 2025 worldwide net sales totaled $220 million Gross margin expanded 490 basis points to 57.5% Second quarter operating income of $8 million and operating margin of 3.9%; constant currency adjusted operating income of $4 million and constant currency adjusted operating margin of 1.7% Raises full year 2025 guidance RICHARDSON, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) — Fossil Group, Inc. (NASDAQ: FOSL) today announced financial results for the fiscal second quarter ended July 5, 2025. In a separate press release today, the Company also announced a comprehensive refinancing plan to strengthen its balance sheet and increase liquidity. “Our second quarter outperformance and continuing momentum reinforces the strength of our turnaround plan,” said Franco Fogliato, CEO. “We delivered a third...

REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended June 30, 2025 and provided a corporate update. “The compelling results we are generating in both CSU and CIndU continue to reinforce our belief that briquilimab has the potential to be a highly differentiated therapy in mast cell-driven diseases,” said Ronald Martell, President and Chief Executive Officer of Jasper. “We continue to generate strong data, with briquilimab driving complete responses in 89% of patients across...